Frontiers | Neprilysin Inhibitors and Bradykinin
Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy | Circulation: Heart Failure
Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy | Circulation: Heart Failure
LCZ696 (Valsarta + sacubitril) | C48H57N6Na3O9 | CID 24755604 - PubChem
Sacubitril calcium | AHU377 | LCZ696 | CAS#149709-62-6 | 1369773-39-6 | 149690-05-1 |angiotensin receptor neprilysin inhibitor | MedKoo Biosciences
Sacubitril – Wikipedia
Heart failure with preserved ejection fraction: emerging drug strategies. - Abstract - Europe PMC
PharmaWiki - Sacubitril
Sacubitril - Wikipedia
Sacubitril/Valsartan (LCZ696) | ARN Inhibitor | MedChemExpress
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. - Abstract - Europe PMC
Neprilysin - Wikipedia
Bio <-> Chem: Back-story on Novartis LCZ696 database links
sacubitril | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
LCZ696 (Valsarta + sacubitril) | C48H57N6Na3O9 | CID 24755604 - PubChem
Sacubitril | New Drug Approvals
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial - The Lancet
Sacubitril | New Drug Approvals
Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy | Circulation: Heart Failure
Bio <-> Chem: Back-story on Novartis LCZ696 database links
SACUBITRIL
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial - The Lancet
Entresto | C96H120N12Na6O21 | CID 71449007 - PubChem
